Global Anti-Obesity Drugs (Anti-obesity Medication) Market

Anti-Obesity Drugs (Anti-obesity Medication) Comprehensive Study by Type (Prescription Medications, Over-the-Counter (OTC) Medications), Sales Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Stores, Others), Age Group (Children & Teenagers, Adults, Senior Citizen), Drug Class (Antipsychotics, Antidepressants, Antiepileptic Drugs, Beta-Blockers, Serotonin Antagonists, Anxiolytics, Others) Players and Region - Global Market Outlook to 2030

Anti-Obesity Drugs (Anti-obesity Medication) Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Anti-Obesity Drugs (Anti-obesity Medication) Market Overview:
Anti-obesity Medication Market includes drugs that help prevent obesity by impacting food intake, energy processing, or fat digestion. These medications are usually prescribed in conjunction with diet and exercise to facilitate proper weight loss practices. They act on several specific lines of action and regulatory circuits in the body with the overall objective of decreasing weight and reversing obesity associate conditions such as cardiovascular disorders and diabetes. This makes some of its key uses to treat obesity, overweight conditions, and other complications associated with them. Some of the trends that still exist in the market are the coming up of new products that are anti-obesity drugs that are better than the previous ones in that they are more effective in their functioning and are safer to use and other facts that come with the coming of age of personalized medicine which seeks to strike off medicines that are customized to patients needs and genetic makeup.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Innovations in Drug Formulation and Development of New Drug Classes for More Effective and Safer Anti-Obesity Medications

Market Growth Drivers:
Change in Lifestyle of People and Increasing Population with Obesities and Growing Awareness of Obesity as a Health Concern and Adoption of OTC Medications

Challenges:
Variable Efficacy and Weight Regain After Discontinuing Medication

Restraints:
Regulatory Approval Process for New Anti-Obesity Medications Can Be Lengthy and Complex That Cause Delay

Opportunities:
Increased Focus on Personalized Anti-Obesity Medications Based On Individual Genetic and Metabolism

Competitive Landscape:
The key players are targeting the innovations of the Solutions with better quality, better technical characteristics. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking upon mergers and acquisitions in order to maintain their presence in the market.
Some of the key players profiled in the report are Novo Nordisk (Denmark), Eli Lilly and Company (United States), Pfizer Inc. (United States), Vivus, Inc. (United States), Orexigen Therapeutics, Inc. (United States), Boehringer Ingelheim (Germany), Rhythm Pharmaceuticals (United States), GlaxoSmithKline plc (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen Inc. (United States), Gelesis (United States) and AstraZeneca plc (United Kingdom). Analyst at AMA Research see United States Players to retain maximum share of Global Anti-Obesity Drugs (Anti-obesity Medication) market by 2030. Considering Market by , the sub-segment i.e. will boost the Anti-Obesity Drugs (Anti-obesity Medication) market.

What Can be Explored with the Anti-Obesity Drugs (Anti-obesity Medication) Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Anti-Obesity Drugs (Anti-obesity Medication) Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Anti-Obesity Drugs (Anti-obesity Medication)
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Anti-Obesity Drugs (Anti-obesity Medication) market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Anti-Obesity Drugs (Anti-obesity Medication) market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Pharmaceutical Companies, Drug Raw Material Providers, Healthcare Service Providers, Government Regulatory Bodies, Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Prescription Medications
  • Over-the-Counter (OTC) Medications
By Sales Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Stores
  • Others

By Age Group
  • Children & Teenagers
  • Adults
  • Senior Citizen

By Drug Class
  • Antipsychotics
  • Antidepressants
  • Antiepileptic Drugs
  • Beta-Blockers
  • Serotonin Antagonists
  • Anxiolytics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Change in Lifestyle of People and Increasing Population with Obesities
      • 3.2.2. Growing Awareness of Obesity as a Health Concern and Adoption of OTC Medications
    • 3.3. Market Challenges
      • 3.3.1. Variable Efficacy and Weight Regain After Discontinuing Medication
    • 3.4. Market Trends
      • 3.4.1. Innovations in Drug Formulation and Development of New Drug Classes for More Effective and Safer Anti-Obesity Medications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-Obesity Drugs (Anti-obesity Medication), by Type, Sales Channel, Age Group, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Anti-Obesity Drugs (Anti-obesity Medication) (Value)
      • 5.2.1. Global Anti-Obesity Drugs (Anti-obesity Medication) by: Type (Value)
        • 5.2.1.1. Prescription Medications
        • 5.2.1.2. Over-the-Counter (OTC) Medications
      • 5.2.2. Global Anti-Obesity Drugs (Anti-obesity Medication) by: Sales Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Specialty Stores
        • 5.2.2.4. Others
      • 5.2.3. Global Anti-Obesity Drugs (Anti-obesity Medication) by: Age Group (Value)
        • 5.2.3.1. Children & Teenagers
        • 5.2.3.2. Adults
        • 5.2.3.3. Senior Citizen
      • 5.2.4. Global Anti-Obesity Drugs (Anti-obesity Medication) by: Drug Class (Value)
        • 5.2.4.1. Antipsychotics
        • 5.2.4.2. Antidepressants
        • 5.2.4.3. Antiepileptic Drugs
        • 5.2.4.4. Beta-Blockers
        • 5.2.4.5. Serotonin Antagonists
        • 5.2.4.6. Anxiolytics
        • 5.2.4.7. Others
      • 5.2.5. Global Anti-Obesity Drugs (Anti-obesity Medication) Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Anti-Obesity Drugs (Anti-obesity Medication): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novo Nordisk (Denmark)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Vivus, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Orexigen Therapeutics, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Boehringer Ingelheim (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Rhythm Pharmaceuticals (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Gelesis (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. AstraZeneca plc (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Sale, by Type, Sales Channel, Age Group, Drug Class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Anti-Obesity Drugs (Anti-obesity Medication) (Value)
      • 7.2.1. Global Anti-Obesity Drugs (Anti-obesity Medication) by: Type (Value)
        • 7.2.1.1. Prescription Medications
        • 7.2.1.2. Over-the-Counter (OTC) Medications
      • 7.2.2. Global Anti-Obesity Drugs (Anti-obesity Medication) by: Sales Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Specialty Stores
        • 7.2.2.4. Others
      • 7.2.3. Global Anti-Obesity Drugs (Anti-obesity Medication) by: Age Group (Value)
        • 7.2.3.1. Children & Teenagers
        • 7.2.3.2. Adults
        • 7.2.3.3. Senior Citizen
      • 7.2.4. Global Anti-Obesity Drugs (Anti-obesity Medication) by: Drug Class (Value)
        • 7.2.4.1. Antipsychotics
        • 7.2.4.2. Antidepressants
        • 7.2.4.3. Antiepileptic Drugs
        • 7.2.4.4. Beta-Blockers
        • 7.2.4.5. Serotonin Antagonists
        • 7.2.4.6. Anxiolytics
        • 7.2.4.7. Others
      • 7.2.5. Global Anti-Obesity Drugs (Anti-obesity Medication) Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-Obesity Drugs (Anti-obesity Medication): by Type(USD Million)
  • Table 2. Anti-Obesity Drugs (Anti-obesity Medication) Prescription Medications , by Region USD Million (2018-2023)
  • Table 3. Anti-Obesity Drugs (Anti-obesity Medication) Over-the-Counter (OTC) Medications , by Region USD Million (2018-2023)
  • Table 4. Anti-Obesity Drugs (Anti-obesity Medication): by Sales Channel(USD Million)
  • Table 5. Anti-Obesity Drugs (Anti-obesity Medication) Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 6. Anti-Obesity Drugs (Anti-obesity Medication) Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 7. Anti-Obesity Drugs (Anti-obesity Medication) Specialty Stores , by Region USD Million (2018-2023)
  • Table 8. Anti-Obesity Drugs (Anti-obesity Medication) Others , by Region USD Million (2018-2023)
  • Table 9. Anti-Obesity Drugs (Anti-obesity Medication): by Age Group(USD Million)
  • Table 10. Anti-Obesity Drugs (Anti-obesity Medication) Children & Teenagers , by Region USD Million (2018-2023)
  • Table 11. Anti-Obesity Drugs (Anti-obesity Medication) Adults , by Region USD Million (2018-2023)
  • Table 12. Anti-Obesity Drugs (Anti-obesity Medication) Senior Citizen , by Region USD Million (2018-2023)
  • Table 13. Anti-Obesity Drugs (Anti-obesity Medication): by Drug Class(USD Million)
  • Table 14. Anti-Obesity Drugs (Anti-obesity Medication) Antipsychotics , by Region USD Million (2018-2023)
  • Table 15. Anti-Obesity Drugs (Anti-obesity Medication) Antidepressants , by Region USD Million (2018-2023)
  • Table 16. Anti-Obesity Drugs (Anti-obesity Medication) Antiepileptic Drugs , by Region USD Million (2018-2023)
  • Table 17. Anti-Obesity Drugs (Anti-obesity Medication) Beta-Blockers , by Region USD Million (2018-2023)
  • Table 18. Anti-Obesity Drugs (Anti-obesity Medication) Serotonin Antagonists , by Region USD Million (2018-2023)
  • Table 19. Anti-Obesity Drugs (Anti-obesity Medication) Anxiolytics , by Region USD Million (2018-2023)
  • Table 20. Anti-Obesity Drugs (Anti-obesity Medication) Others , by Region USD Million (2018-2023)
  • Table 21. South America Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2018-2023)
  • Table 22. South America Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 23. South America Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 24. South America Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 25. South America Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 26. Brazil Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 27. Brazil Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 28. Brazil Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 29. Brazil Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 30. Argentina Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 31. Argentina Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 32. Argentina Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 33. Argentina Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 34. Rest of South America Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 35. Rest of South America Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 36. Rest of South America Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 37. Rest of South America Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 38. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2018-2023)
  • Table 39. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 40. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 41. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 42. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 43. China Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 44. China Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 45. China Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 46. China Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 47. Japan Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 48. Japan Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 49. Japan Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 50. Japan Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 51. India Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 52. India Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 53. India Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 54. India Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 55. South Korea Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 56. South Korea Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 57. South Korea Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 58. South Korea Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 59. Taiwan Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 60. Taiwan Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 61. Taiwan Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 62. Taiwan Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 63. Australia Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 64. Australia Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 65. Australia Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 66. Australia Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 71. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2018-2023)
  • Table 72. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 73. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 74. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 75. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 76. Germany Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 77. Germany Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 78. Germany Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 79. Germany Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 80. France Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 81. France Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 82. France Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 83. France Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 84. Italy Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 85. Italy Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 86. Italy Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 87. Italy Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 88. United Kingdom Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 89. United Kingdom Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 90. United Kingdom Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 91. United Kingdom Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 92. Netherlands Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 93. Netherlands Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 94. Netherlands Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 95. Netherlands Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 96. Rest of Europe Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 97. Rest of Europe Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 98. Rest of Europe Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 99. Rest of Europe Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 100. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2018-2023)
  • Table 101. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 102. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 103. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 104. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 105. Middle East Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 106. Middle East Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 107. Middle East Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 108. Middle East Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 109. Africa Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 110. Africa Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 111. Africa Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 112. Africa Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 113. North America Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2018-2023)
  • Table 114. North America Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 115. North America Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 116. North America Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 117. North America Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 118. United States Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 119. United States Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 120. United States Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 121. United States Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 122. Canada Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 123. Canada Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 124. Canada Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 125. Canada Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 126. Mexico Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2018-2023)
  • Table 127. Mexico Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2018-2023)
  • Table 128. Mexico Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2018-2023)
  • Table 129. Mexico Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2018-2023)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Anti-Obesity Drugs (Anti-obesity Medication): by Type(USD Million)
  • Table 143. Anti-Obesity Drugs (Anti-obesity Medication) Prescription Medications , by Region USD Million (2025-2030)
  • Table 144. Anti-Obesity Drugs (Anti-obesity Medication) Over-the-Counter (OTC) Medications , by Region USD Million (2025-2030)
  • Table 145. Anti-Obesity Drugs (Anti-obesity Medication): by Sales Channel(USD Million)
  • Table 146. Anti-Obesity Drugs (Anti-obesity Medication) Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 147. Anti-Obesity Drugs (Anti-obesity Medication) Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 148. Anti-Obesity Drugs (Anti-obesity Medication) Specialty Stores , by Region USD Million (2025-2030)
  • Table 149. Anti-Obesity Drugs (Anti-obesity Medication) Others , by Region USD Million (2025-2030)
  • Table 150. Anti-Obesity Drugs (Anti-obesity Medication): by Age Group(USD Million)
  • Table 151. Anti-Obesity Drugs (Anti-obesity Medication) Children & Teenagers , by Region USD Million (2025-2030)
  • Table 152. Anti-Obesity Drugs (Anti-obesity Medication) Adults , by Region USD Million (2025-2030)
  • Table 153. Anti-Obesity Drugs (Anti-obesity Medication) Senior Citizen , by Region USD Million (2025-2030)
  • Table 154. Anti-Obesity Drugs (Anti-obesity Medication): by Drug Class(USD Million)
  • Table 155. Anti-Obesity Drugs (Anti-obesity Medication) Antipsychotics , by Region USD Million (2025-2030)
  • Table 156. Anti-Obesity Drugs (Anti-obesity Medication) Antidepressants , by Region USD Million (2025-2030)
  • Table 157. Anti-Obesity Drugs (Anti-obesity Medication) Antiepileptic Drugs , by Region USD Million (2025-2030)
  • Table 158. Anti-Obesity Drugs (Anti-obesity Medication) Beta-Blockers , by Region USD Million (2025-2030)
  • Table 159. Anti-Obesity Drugs (Anti-obesity Medication) Serotonin Antagonists , by Region USD Million (2025-2030)
  • Table 160. Anti-Obesity Drugs (Anti-obesity Medication) Anxiolytics , by Region USD Million (2025-2030)
  • Table 161. Anti-Obesity Drugs (Anti-obesity Medication) Others , by Region USD Million (2025-2030)
  • Table 162. South America Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2025-2030)
  • Table 163. South America Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 164. South America Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 165. South America Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 166. South America Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 167. Brazil Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 168. Brazil Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 169. Brazil Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 170. Brazil Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 171. Argentina Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 172. Argentina Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 173. Argentina Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 174. Argentina Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 175. Rest of South America Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 176. Rest of South America Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 177. Rest of South America Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 178. Rest of South America Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 179. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2025-2030)
  • Table 180. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 181. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 182. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 183. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 184. China Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 185. China Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 186. China Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 187. China Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 188. Japan Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 189. Japan Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 190. Japan Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 191. Japan Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 192. India Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 193. India Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 194. India Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 195. India Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 196. South Korea Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 197. South Korea Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 198. South Korea Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 199. South Korea Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 200. Taiwan Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 201. Taiwan Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 202. Taiwan Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 203. Taiwan Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 204. Australia Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 205. Australia Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 206. Australia Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 207. Australia Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 212. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2025-2030)
  • Table 213. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 214. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 215. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 216. Europe Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 217. Germany Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 218. Germany Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 219. Germany Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 220. Germany Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 221. France Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 222. France Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 223. France Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 224. France Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 225. Italy Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 226. Italy Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 227. Italy Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 228. Italy Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 229. United Kingdom Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 230. United Kingdom Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 231. United Kingdom Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 232. United Kingdom Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 233. Netherlands Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 234. Netherlands Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 235. Netherlands Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 236. Netherlands Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 237. Rest of Europe Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 238. Rest of Europe Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 239. Rest of Europe Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 240. Rest of Europe Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 241. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2025-2030)
  • Table 242. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 243. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 244. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 245. MEA Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 246. Middle East Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 247. Middle East Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 248. Middle East Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 249. Middle East Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 250. Africa Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 251. Africa Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 252. Africa Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 253. Africa Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 254. North America Anti-Obesity Drugs (Anti-obesity Medication), by Country USD Million (2025-2030)
  • Table 255. North America Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 256. North America Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 257. North America Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 258. North America Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 259. United States Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 260. United States Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 261. United States Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 262. United States Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 263. Canada Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 264. Canada Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 265. Canada Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 266. Canada Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 267. Mexico Anti-Obesity Drugs (Anti-obesity Medication), by Type USD Million (2025-2030)
  • Table 268. Mexico Anti-Obesity Drugs (Anti-obesity Medication), by Sales Channel USD Million (2025-2030)
  • Table 269. Mexico Anti-Obesity Drugs (Anti-obesity Medication), by Age Group USD Million (2025-2030)
  • Table 270. Mexico Anti-Obesity Drugs (Anti-obesity Medication), by Drug Class USD Million (2025-2030)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-Obesity Drugs (Anti-obesity Medication): by Type USD Million (2018-2023)
  • Figure 5. Global Anti-Obesity Drugs (Anti-obesity Medication): by Sales Channel USD Million (2018-2023)
  • Figure 6. Global Anti-Obesity Drugs (Anti-obesity Medication): by Age Group USD Million (2018-2023)
  • Figure 7. Global Anti-Obesity Drugs (Anti-obesity Medication): by Drug Class USD Million (2018-2023)
  • Figure 8. South America Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 9. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 10. Europe Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 11. MEA Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 12. North America Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 13. Global Anti-Obesity Drugs (Anti-obesity Medication) share by Players 2023 (%)
  • Figure 14. Global Anti-Obesity Drugs (Anti-obesity Medication) share by Players (Top 3) 2023(%)
  • Figure 15. Global Anti-Obesity Drugs (Anti-obesity Medication) share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 18. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 19. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Vivus, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Vivus, Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Orexigen Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Orexigen Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 29. Rhythm Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 30. Rhythm Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 31. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2023
  • Figure 33. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 35. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Gelesis (United States) Revenue, Net Income and Gross profit
  • Figure 38. Gelesis (United States) Revenue: by Geography 2023
  • Figure 39. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Global Anti-Obesity Drugs (Anti-obesity Medication): by Type USD Million (2025-2030)
  • Figure 42. Global Anti-Obesity Drugs (Anti-obesity Medication): by Sales Channel USD Million (2025-2030)
  • Figure 43. Global Anti-Obesity Drugs (Anti-obesity Medication): by Age Group USD Million (2025-2030)
  • Figure 44. Global Anti-Obesity Drugs (Anti-obesity Medication): by Drug Class USD Million (2025-2030)
  • Figure 45. South America Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 46. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 47. Europe Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 48. MEA Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
  • Figure 49. North America Anti-Obesity Drugs (Anti-obesity Medication) Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novo Nordisk (Denmark)
  • Eli Lilly and Company (United States)
  • Pfizer Inc. (United States)
  • Vivus, Inc. (United States)
  • Orexigen Therapeutics, Inc. (United States)
  • Boehringer Ingelheim (Germany)
  • Rhythm Pharmaceuticals (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Amgen Inc. (United States)
  • Gelesis (United States)
  • AstraZeneca plc (United Kingdom)
Select User Access Type

Key Highlights of Report


Sep 2024 223 Pages 64 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-Obesity Drugs (Anti-obesity Medication) Market Quantitative research analysis
Global Anti-Obesity Drugs (Anti-obesity Medication) Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Anti-Obesity Drugs (Anti-obesity Medication) market are Novo Nordisk (Denmark), Eli Lilly and Company (United States), Pfizer Inc. (United States), Vivus, Inc. (United States), Orexigen Therapeutics, Inc. (United States), Boehringer Ingelheim (Germany), Rhythm Pharmaceuticals (United States), GlaxoSmithKline plc (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen Inc. (United States), Gelesis (United States) and AstraZeneca plc (United Kingdom), to name a few.
"Innovations in Drug Formulation and Development of New Drug Classes for More Effective and Safer Anti-Obesity Medications" is seen as one of major influencing trends for Anti-Obesity Drugs (Anti-obesity Medication) Market during projected period 2023-2030.
Prescription Medications segment in Global market to hold robust market share owing to "Change in Lifestyle of People and Increasing Population with Obesities ".

Know More About Global Anti-Obesity Drugs (Anti-obesity Medication) Market Report?

Have a Query? Click Here

Other Related Reports

Drugs Comprehensive Study by Type (Stimulants (e.g. Cocaine), Depressants (e.g. Alcohol), Opium-Related Painkillers (e.g. Heroin), Hallucinogens (e.g. Lsd)), Application (Hospitals, Clinics, Diagnost...
$ 3800
Chemotherapy-Induced Nausea Vomiting (CINV) Drugs Comprehensive Study by Type (Acute Emesis, Delayed Emesis, Anticipatory Emesis, Refractory Emesis), Drug Type (Branded, Generics), Therapy (Nk-1 Rece...
$ 4000
Nitazoxanide Drug Comprehensive Study by Form (Tablet, Powder for Suspension), Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), Treatment (Diarrhea, Cryptosporidium ...
$ 3800
GP Vaccination Comprehensive Study by Type (DNA, Non-replicating Viral Vector, RNA, Others), End-users (Adults, Children), Vaccine (Corbevax Vaccine, Covaxin Vaccine, Covishield Vaccine, Sputnik Ligh...
$ 3500
Catalepsy Treatment Comprehensive Study by Treatment (Antipsychotic medications {Drugs, Psychotherapy, Others}, Muscle relaxants), Route of Administration (Oral, Parenteral, Others), End-Users (Hos...
$ 3800
Vasoconstrictor Drugs Comprehensive Study by Application (Clinic, Hospital), Administration (Intravenous, Oral), Side Effect (Irregular Heartbeats, Dizziness, Diarrhea, High Blood Sugar), Distributi...
$ 3800